Prof. Jonathan R Strosberg, who leads the NET Division at Moffitt Cancer Center, Tampa, FL, USA, summarizes the scientific and clinical evidence for GEP-NET treatment strategies in 2021.1/3 Next Interview
Thorvardur R Halfdanarson, Professor of Oncology at the Mayo Clinic School of Medicine, Rochester, MN, USA, explores the potential impact of new data on clinical practice relevant to the management of GEP-NETs.2/3 Next Interview
Diane Reidy-Lagunes, medical oncologist at the Memorial Sloan Kettering Cancer Center, New York, USA, appraises the need for a multidisciplinary approach to treatment and monitoring, and highlights the latest strategies for progressive disease management.3/3 Take CME Test
Overview & Learning Objectives
In this activity, experts in the field of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) explore how recent scientific and clinical advances may optimize approaches to the medical management of GEP-NETs in 2021, and beyond.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of oncologists, gastro-oncologists, gastroenterologists, radiologists and endocrinologists involved in the management of gastroenteropancreatic neuroendocrine tumours.
USF Health adheres to The Standards for Integrity and Independence in Accredited Continuing Education in all of its continuing professional development activities. It is USF Health’s policy that all persons in a position to influence content in this activity disclose any financial relationship with an ineligible organization. USF Health has mitigated all conflicts of interest.
Prof. Jonathan R Strosberg discloses: Consultancy fees from Novartis. Grants/research support fees from Novartis. Speaker fees from Ipsen.
Prof. Thorvardur R Halfdanarson discloses: Advisory board/panel fees from Advanced Accelerator Applications, Crinetics Pharmaceuticals, Curium Pharma, Ipsen, ITM Isotopen Technologien München AG and Novartis. Grants/research support fees from Advanced Accelerator Applications and Novartis.
Dr Diane Reidy-Lagunes discloses: Advisory board/panel fees from Advanced Accelerator Applications, Chiasma Inc., ITM Isotopen Technologien München AG and OncoLogics. Grants/research support fees from Ipsen and Novartis.
Olivia Pane, PharmD, CDCES has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Paul Taylor has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 12 August 2021. Date credits expire: 12 August 2022.
If you have any questions regarding credit please contact firstname.lastname@example.org
After watching this activity, participants should be better able to:
- Interpret the data supporting new and emerging treatment options to improve outcomes for patients with GEP-NETs
- Analyse current guidelines for the therapeutic agents to treat GEP-NETs
- Appraise the criteria for assessing disease progression in GEP-NETs, and how they impact treatment choice